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OBJECTIVE—We tested the hypothesis that an increase in
insulin per se, i.e., in the absence of zinc, suppresses glucagon
secretion during euglycemia and that a decrease in insulin per se
stimulates glucagon secretion during hypoglycemia in humans.
RESEARCH DESIGN AND METHODS—We measured plasma
glucagon concentrations in patients with type 1 diabetes infused
with the zinc-free insulin glulisine on three occasions. Glulisine
was infused with clamped euglycemia (95 mg/dl [5.3 mmol/l])
from 0 to 60 min on all three occasions. Then, glulisine was
discontinued with clamped euglycemia or with clamped hypogly-
cemia (55 mg/dl [3.0 mmol/l]) or continued with clamped
hypoglycemia from 60 to 180 min.
RESULTS—Plasma glucagon concentrations were suppressed
by 13  3, 9  3, and 12  2 pg/ml (3.7  0.9, 2.6  0.9,
and 3.4  0.6 pmol/l), respectively, (all P  0.01) during
zinc-free hyperinsulinemic euglycemia over the ﬁrst 60 min.
Glucagon levels remained suppressed following a decrease in
zinc-free insulin with euglycemia (14  3 pg/ml [4.0  0.9
pmol/l]) and during sustained hyperinsulinemia with hypoglyce-
mia (14  2 pg/ml [4.0  0.6 pmol/l]) but increased to 3 
3 pg/ml (0.9  0.9 pmol/l) (P  0.01) following a decrease in
zinc-free insulin with hypoglycemia over the next 120 min.
CONCLUSIONS—These data indicate that an increase in insu-
lin per se suppresses glucagon secretion and a decrease in insulin
per se, in concert with a low glucose concentration, stimulates
glucagon secretion. Thus, they document that insulin is a -cell
secretory product that, in concert with glucose and among other
signals, reciprocally regulates -cell glucagon secretion in
humans. Diabetes 59:2936–2940, 2010
T
he regulation of pancreatic islet -cell glucagon
secretion by nutrients, hormones, neurotrans-
mitters, and drugs is complex and incompletely
understood (1–8). It involves direct signaling of
-cells (1) and indirect signaling of -cells by -cell (2–4)
and -cell (5) secretory products, the autonomic nervous
system (6,7), and gut incretins (8). Among the intraislet
mechanisms, there is evidence that indirect reciprocal
-cell–mediated signaling of -cells normally predomi-
nates over direct -cell signaling in the regulation of
glucagon secretion in humans (9–13). The physiological
concept is as follows: 1)A-cell secretory product, or
products, tonically restrains -cell glucagon secretion dur-
ing postabsorptive euglycemia. 2) A decrease in -cell
secretion, in concert with a low -cell glucose concentra-
tion, signals an increase in -cell glucagon secretion
during hypoglycemia (9–12). 3) An increase in -cell
secretion negates direct -cell stimulation and thus results
in no change or even suppression of -cell glucagon
secretion following a mixed meal (13).
Among the various candidate signaling molecules—
insulin, zinc, -aminobutyric acid, and amylin among oth-
ers (4)—there is evidence that insulin is a -cell secretory
product that normally restrains basal -cell glucagon
secretion (14). First, administered insulin suppresses glu-
cagon secretion in several species (4,14,15) including
humans (16). However, most available insulin prepara-
tions contain zinc and zinc is cosecreted with insulin from
-cells and it has been reported that a decrease in pancre-
atic arterial zinc, but not in insulin depleted of zinc,
increases glucagon secretion during hypoglycemia in
streptozotocin diabetic rats, leading the authors to con-
clude that the inhibitory -cell secretory product is zinc—
not insulin (17). Second, perfusion of the rat (3) and the
human (18) pancreas (and incubation of rat islets [15])
with an antibody to insulin increases glucagon release.
Because insulin circulates as a zinc-free monomer (19),
that ﬁnding seemingly implicates insulin directly as an
-cell inhibitory factor and suggests that zinc is not the
only -cell product that reciprocally regulates -cell glu-
cagon secretion. However, it could be reasoned that the
antibody binds insulin-zinc complexes before they dis-
sociate at physiological pH and with dilution. Third,
ﬁndings—that siRNA-mediated knockdown of insulin
receptors prevented the effect of low glucose concentra-
tions to increase glucagon release from isolated mouse
islets (20) and that blockade of insulin signaling with the
phosphatidylinositol 3-kinase inhibitor wortmannin pre-
vented the effect of high glucose concentrations to de-
crease glucagon release from isolated rat and human islets
(21)—also appear to implicate insulin as the relevant
-cell secretory product.
We tested the hypothesis that an increase in insulin per
se, i.e., in the absence of an increase in zinc, suppresses
glucagon secretion during euglycemia and that a decrease
in insulin per se, in concert with low glucose concentra-
tions, stimulates glucagon secretion in humans. To do so,
we studied patients with type 1 diabetes, individuals with
essentially no endogenous insulin secretion and no -cell
glucagon secretory response to hyperinsulinemic hypogly-
cemia (22–29) but viable -cells as evidenced by a gluca-
gon secretory response to administered amino acids
(22,30–32), on three separate occasions. Plasma glucagon
concentrations were measured during infusion of the
zinc-free insulin glulisine with clamped euglycemia over 60
min on all three occasions. Then, glucagon concentrations
were measured following discontinuation of glulisine, to
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zinc-free insulin levels, over 120 min with clamped eugly-
cemia on one occasion or clamped hypoglycemia on
another occasion. On a third occasion, glucagon levels
were measured during sustained glulisine infusion with
clamped hypoglycemia. The data document 1) a decrease
in plasma glucagon during zinc-free hyperinsulinemic eu-
glycemia and 2) an increase in plasma glucagon following
a decrease in zinc-free insulin during hypoglycemia but not
following a decrease in insulin without hypoglycemia or
during hypoglycemia without a decrease in insulin.
RESEARCH DESIGN AND METHODS
Seventeen patients with type 1 diabetes gave written consent to participate in
this study, which was approved by the Washington University Human Re-
search Protection Ofﬁce and conducted at the Washington University Clinical
Research Unit. Eight were women, and nine were men. The mean  SD age
was 30  10 years, BMI 26.1  3.9 kg/m
2, duration of type 1 diabetes 16  9
years, and A1C 7.5  0.8%. With unmeasurably low values assigned the assay
detection limit of 0.1 ng/ml (0.03 nmol/l), their mean fasting C-peptide
concentration was 0.2  0.1 ng/ml (0.07  0.03 nmol/l). Exclusion criteria
included a serum creatinine concentration 	1.5 mg/dl, untreated proliferative
retinopathy, or clinical evidence of autonomic neuropathy; known macrovas-
cular or central nervous system disease, anemia, or pregnancy; or potentially
interfering medications. Eight were using a multiple daily injection insulin
regimen with a long-acting insulin analog as the basal insulin and a rapid-
acting insulin analog as the prandial insulin, and nine were using continuous
subcutaneous insulin infusion with a rapid-acting insulin analog.
The patients took their last dose of long-acting insulin, if used, the morning
of the day prior to each study and managed their diabetes with a rapid-acting
insulin until they reported to the Clinical Research Unit that evening. They
then fasted overnight and their plasma glucose concentrations were main-
tained at 100 mg/dl (5.6 mmol/l) with variable doses of intravenous regular
insulin (Novolin R; Novo Nordisk Inc, Princeton, NJ). On the morning of each
study, lines were inserted into an antecubital vein for infusions and into a
hand vein with that hand subsequently kept in a 55°C plexiglas box for
arterialized venous sampling. The patients remained supine through the
remainder of the study. Blood samples were obtained, and heart rates and
blood pressures (Propaq Encore; Protocol Systems, Beaverton, OR) were
recorded, at 15-min intervals from 15 to 210 min. Then 5.0 g arginine was
injected intravenously and additional blood samples were obtained at 213,
215, and 217 min (3, 5, and 7 min after arginine injection). From 0 to 60 min,
insulin glulisine (Apidra; sanoﬁ-aventis U.S., Bridgewater, NJ) was infused
intravenously in a dose of 12.0 mU  kg
1  min
1 and, based on bedside plasma
glucose measurements every 5 min, glucose was infused intravenously to
clamp plasma glucose concentrations at 95 mg/dl (5.3 mmol/l). Then,
glulisine infusions were discontinued and, in random sequence, plasma
glucose concentrations were either held at 95 mg/dl (5.3 mmol/l) or clamped
at 55 mg/dl (3.0 mmol/l) from 60 to 180 min. On a subsequent occasion,
glulisine infusion was continued to 180 min and plasma glucose concentra-
tions were clamped at 55 mg/dl (3.0 mmol/l) in 12 of the patients.
Analytical methods. Plasma glucose concentrations were measured with a
glucose oxidase method (YSI Glucose Analyzer, Yellow Springs Instruments,
Yellow Springs, OH). Plasma C-peptide, growth hormone, and cortisol con-
centrations were measured with two-site chemiluminescent assays (Immulite
1000; Siemens, Los Angeles, CA). Because insulin glulisine does not cross-
react in the Immulite insulin assay, an older insulin radioimmunoassay (33)
was used to estimate plasma glulisine concentrations. Preliminary data
indicated that the latter radioimmunoassay detects 75–80% of diluted
glulisine based on the concentration stated on the label. Plasma glucagon and
pancreatic polypeptide concentrations were measured with Linco radioimmu-
noassays (Millipore, Temecula, CA). Plasma epinephrine and norepinephrine
were measured with a single isotope derivative (radioenzymatic) method (34).
Blood lactate (35) and serum nonesteriﬁed fatty acids (36) were measured
with enzymatic methods. Symptoms were quantitated by asking the patients to
score (from 0, none, to 6, severe) each of 12 symptoms classiﬁed on the basis
of our published data (37): six neurogenic symptoms (adrenergic: heart
pounding, shaky, tremulous, and nervous/anxious; cholinergic: sweaty, hun-
gry, and tingling) and six neuroglycopenic symptoms (difﬁculty thinking/
confused, tired/drowsy, weak, warm, faint, and dizzy).
Statistical methods. Except where speciﬁed otherwise, data are reported as
means  SE. Time and condition-related variables were analyzed by repeated-
measures mixed-model analysis of variance. P values 0.05 were considered
to indicate signiﬁcant differences.
RESULTS
Plasma insulin glulisine, glucose, and glucagon. Infu-
sion of insulin glulisine raised mean plasma insulin con-
centrations to 500 
U/ml (3,000 pmol/l) by 60 min.
Following discontinuation of glulisine infusions at 60 min,
mean insulin levels fell sharply, reaching baseline levels
before 180 min, in both studies; insulin levels continued to
rise when glulisine infusions were continued from 60 to
180 min in the third study (Fig. 1).
When insulin glulisine was infused from 0 to 60 min,
plasma glucose concentrations were held, by glucose
infusion, at 95 mg/dl (5.3 mmol/l) on all three occasions.
When insulin glulisine infusions were discontinued after
60 min, glucose levels were held at 95 mg/dl (5.3 mmol/l)
on one occasion and were lowered and then held at 55
mg/dl (3.0 mmol/l) on the other occasion. When insulin
glulisine infusion was continued from 60 to 180 min,
glucose levels were lowered and then held at 55 mg/dl
(3.0 mmol/l).
Mean  SE plasma glucagon concentrations were 67 
4, 64  4, and 46  3 pg/ml (19.2  1.1, 18.4  1.1, and
13.2  1.1 pmol/l), respectively, at 0 min and decreased to
54  3, 55  4, and 34  3 pg/ml (15.5  0.9, 15.8  1.1, and
9.8  0.9 pmol/l) during glulisine hyperinsulinemia at 60
min. Thus, plasma glucagon levels were suppressed by
13  3, 9  3, and 12  2 pg/ml (3.7  0.9, 2.6 
0.9, and 3.4  0.6 pmol/l) during zinc-free hyperinsuline-
mic euglycemia from 0 to 60 min (all P  0.01). Glucagon
levels remained suppressed following a decrease in zinc-
free insulin after 60 min with euglycemia to 180 min
(14  3 pg/ml [4.0  0.9 pmol/l]) and during sustained
zinc-free hyperinsulinemia with hypoglycemia from 60 to
180 min (14  2 pg/ml [4.0  0.6 pmol/l]) but increased
following a decrease in zinc-free insulin after 60 min with
hypoglycemia from 60 to 180 min to 3  3 pg/ml (0.9 
0.09 pmol/l) (P  0.01).
Other neuroendocrine and metabolism measure-
ments and symptoms, heart rate, and blood pres-
sures. None of the other neuroendocrine levels displayed
the pattern of glucagon. Plasma pancreatic polypeptide
concentrations tended to decline during zinc-free hyperin-
sulinemic euglycemia but increased similarly during hypo-
glycemia, with falling insulin levels and sustained
hyperinsulinemia. The latter was also true for plasma
epinephrine, growth hormone, and cortisol concentra-
tions. Blood lactate concentrations rose similarly during
hyperinsulinemia on all three occasions. Serum nonesteri-
ﬁed fatty acid concentrations were suppressed (Fig. 2).
Mean symptom scores, heart rates, and systolic and dia-
stolic blood pressures were similar on all three occasions
(data not shown).
DISCUSSION
Despite a body of evidence indicating that insulin is a
-cell secretory product that reciprocally regulates
-cell glucagon secretion (rev. in 4,14,16), it has been
concluded that zinc, not insulin, is the relevant -cell
secretory product (17). Therefore, we tested the hypoth-
esis that an increase in insulin per se, i.e., in the absence
of a change in zinc, suppresses glucagon secretion
during euglycemia and that a decrease in insulin per se
stimulates glucagon secretion during hypoglycemia in
humans. To do so, we measured plasma glucagon con-
centrations in demonstrably endogenous insulin-deﬁ-
cient patients with type 1 diabetes during controlled
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fusion of the zinc-free commercial insulin glulisine
(38)—combined with controlled euglycemia and hypo-
glycemia. Glulisine was ﬁrst infused for 60 min with
clamped euglycemia on three occasions. Then glulisine
was 1) discontinued with euglycemia maintained over
2h ,2) discontinued with hypoglycemia maintained over
2h ,a n d3) continued with hypoglycemia maintained
over 2 h.
Our hypothesis was conﬁrmed. First, a sharp increase in
zinc-free insulin suppressed plasma glucagon concentra-
tions during clamped euglycemia on all three occasions.
Second, plasma glucagon concentrations remained sup-
pressed following a sharp decrease in systemic, and thus
-cell, zinc-free insulin with clamped euglycemia and
during continued zinc-free hyperinsulinemia with clamped
hypoglycemia, but plasma glucagon concentrations in-
creased following a sharp decrease in zinc-free insulin
with clamped hypoglycemia. These data also illustrate that
a decrease in insulin, as demonstrated earlier for a de-
crease in -cell secretion (12), signals an increase in
glucagon secretion only in the setting of hypoglycemia.
The decrease in zinc-free insulin did not restore a
normal glucagon response to hypoglycemia in these pa-
tients with type 1 diabetes. However, that would not be
expected even if signaling of -cells were normalized.
Patients with type 1 diabetes have glucagon secretory
responses to direct -cell stimuli such as oral alanine (30),
intravenous amino acids (31), and oral amino acids (32).
However, their maximum stimulated plasma glucagon
concentrations are only 20–25% those of nondiabetic
individuals (30–32). That ﬁnding was also documented in
the present study. The peak glucagon response to intrave-
nous arginine was 25% of that in our earlier study of
nondiabetic individuals (12). The extent to which that
represents a decreased glucagon response per -cell, a
decrease in -cell mass (39), or both in type 1 diabetes is
not known.
Normally, insulin and zinc ions create a hexameric
crystalline structure stored in pancreatic -cell secretory
granules at pH 5.5. Upon secretion, the hexameric insulin
structure dissociates into the biologically active insulin
monomer and zinc ions—probably because of a combina-
tion of a rapid decrease in zinc ion pressure and the
change in pH from 5.5 to 7.4 (19). In our patients with type
1 diabetes and little if any endogenous insulin secretion,
the circulating insulin was almost exclusively glulisine.
Glulisine contains no exogenous zinc (38) and, because
insulin circulates as a zinc-free monomer at physiological
pH (19), it would not have bound endogenous zinc. Thus,
by changing the rate of glulisine infusion we were able to
change insulin action independent of zinc action.
There are limitations to this study. First, the changes in
plasma glucagon concentrations were rather small in
relation to the total measured values. The radioimmuno-
assay used detects species in addition to 3,500 Da gluca-
gon, although changes in measured values are thought to
represent changes in biologically active glucagon (40,41).
Second, while the ﬁrst two studies (decrements in zinc-
free insulin with euglycemia and with hypoglycemia) were
performed in random sequence, the second control (no
decrement in insulin with hypoglycemia) was performed
later in a subset of the patients. The latter may explain the
lower mean glucagon levels in that limb. Third, we used a
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FIG. 1. Mean  SE plasma insulin and glucose concentrations and change () in plasma glucagon concentrations in patients with type 1 diabetes
during infusions of zinc-free insulin glulisine with clamped euglycemia from 0 to 60 min on three occasions (decrements in plasma glucagon all
P < 0.01) and following 1) discontinuation of insulin glulisine with clamped euglycemia (E), 2) discontinuation of insulin glulisine with clamped
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60 to 180 min. Arg, arginine.
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normal -cell insulin concentrations. That may not have
been necessary. Fourth, because an effect of a decrease in
zinc to stimulate glucagon secretion during hypoglycemia
in an insulin-deﬁcient model has already been demon-
strated (17,42), we did not document that a decrease in a
zinc-containing insulin also produces a hypoglycemia-
associated increment in glucagon secretion in patients
with type 1 diabetes.
We have no clear explanation for the difference
between our ﬁnding and that of Zhou et al. (17), who
found no increase in glucagon secretion when insulin
from which zinc had been removed was discontinued
during hypoglycemia in diabetic rats. They studied
rats, and we studied humans. Their sample size was
about one-third of our sample size. While they provided
evidence that very high concentrations of their zinc-
depleted insulin preparation (i.e., 1.0 
mol/l) was bio-
logically active in vitro, dose-response data indicating
that biological activity was not reduced by the zinc
removal process were not presented.
Again, the regulation of glucagon secretion is complex
and not limited to effects of insulin or of other -cell
secretory products (1–8,43). For example, the decrease in
nonesteriﬁed fatty acids may have been involved in the
suppression of glucagon secretion during hyperinsuline-
mic euglycemia and the increase in epinephrine may have
been involved in the stimulation of glucagon secretion
during hypoinsulinemic hypoglycemia in our studies.
The ﬁnding that -cell secretion (9–13), including that
by insulin (present data), reciprocally regulates -cell
glucagon secretion in humans is potentially clinically
relevant (13). Loss of the glucagon response to hypogly-
cemia in type 1 diabetes and advanced type 2 diabetes and
less suppression of glucagon following a meal in diabetes
may both be the result, at least in part, of -cell failure
(13). The former is thought to be relevant to the pathogen-
esis of iatrogenic hypoglycemia and the latter to that of
hyperglycemia in diabetes (12,13,40).
In conclusion, these data indicate that insulin per se
suppresses glucagon secretion during euglycemia and that
a decrease in insulin per se, in concert with low glucose
levels, signals an increase in glucagon secretion during
hypoglycemia. Thus, they document that insulin is a -cell
secretory product that, in concert with glucose and among
other signals, reciprocally regulates -cell glucagon secre-
tion in humans.
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